Abstract
The advances of medical technology have resulted in a population of patients at increased risk of serious infections from opportunistic pathogens. Despite the availability of major new antimicrobial agents with in vitro activity, Pseudomonas aeruginosa has emerged as the most common cause of hospital-acquired pneumonia with a mortality of 50%–100%. A recent publication of bacteremia from 1984 to 1987 revealed a mortality of 51.1% at the time of discharge [1]. This mortality is approximately twofold higher than with other gram-negative pathogens or with gram-positive bacterial infections.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Roberts FJ, Geere IW, Coldman A (1991) A Three-year Study of Positive Blood Cultures with Emphasis on Prognosis. Rev Infect Dis 13:34–46
Anonymous (1984) Nosocomial infection surveillance: CDC morbidity and mortality weekly report, vol 35, pp. 17ss–29ss
Pennington JE (1990) Pseudomonas aeruginosa vaccines and immunotherapy. Infect Dis Clin North Am 4/2:259–270
Collins MS, Roby RE (1984) Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa. Am J Med 76: 168–174
Pennington JE (1979) Lipopolysaccharide Pseudomonas vaccine: efficacy against pulmonary infection with Pseudomonas aeruginosa. J Infect Dis 140:73–80
Pennington JE, Peir GB, Small GJ (1986) Efficacy of intravenous immune globulin for treatment of experimental Pseudomonas aeruginosa. J Crit Care 1:4–10
Young LS (1972) Human immunity to Pseudomonas aeruginosa IL Relationship between heat-stable Opsonins and type-specific lipopolysaccharides. J Infect Dis 126:277–287
Alexander JW, Fisher MW (1974) Immunization against Pseudomonas in infection after thermal injury. J Infect Dis 130 [Suppl]:S152–S158
Pennington JE, Small GJ (1987) Passive immune therapy for experimental Pseudomonas aeruginosa pneumonia in the neutropenic host. J Infect Dis 155:973–978
Pennington JE, Small GJ, Lostrom ME et al. (1986) Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia. Infect Immun 54:239–244
Sadoff JC, Wright DC, Futrovsky S et al. (1986) Characterization of mouse monoclonal antibodies directed against Pseudomonas aeruginosa lipopolysaccharides. Antibiot Chemother 36:134–146
Sawada S, Suzuki M, Kawamura T et al. (1984) Protection against infection with Pseudomonas aeruginosa by passive transfer of monoclonal antibodies to lipopolysaccharides and outer membrane proteins. J Infect Dis 150:570–576
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag, Berlin Heidelberg
About this chapter
Cite this chapter
Saravolatz, L., Kilborn, J., Pennington, J. (1993). Immunotherapeutic Strategies for Passive Immunization Against Pseudomonas aeruginosa . In: Faist, E., Meakins, J.L., Schildberg, F.W. (eds) Host Defense Dysfunction in Trauma, Shock and Sepsis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77405-8_155
Download citation
DOI: https://doi.org/10.1007/978-3-642-77405-8_155
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-77407-2
Online ISBN: 978-3-642-77405-8
eBook Packages: Springer Book Archive